Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-15 | 2024-03 | 0 | -0.52 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -1.48 | N/A | N/A |
2023-09-27 | 2023-06 | 0 | 0.16 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -1.93 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-08 | Maxim Group | Upgrade | Buy | |
2023-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-04-15 | CANTRELL GARY V. | Director | 204.09K | Stock Award(Grant) |
2023-06-13 | DISBROW JOSHUA R. | Chief Executive Officer | 71.59K | Purchase |
2023-08-10 | DOCKERY CARL C | Director | 8.94K | Stock Award(Grant) |
2021-04-07 | HECHT BETH P | Director | 9.05K | Stock Award(Grant) |
2023-08-15 | JAIN ABHINAV | Director | 8.00K | Stock Award(Grant) |
2023-08-10 | LIU VIVIAN H | Director | 1.84K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Nantahala Capital Management, LLC | 1.09M | 1.74M | 19.65% |
2023-06-29 | Stonepine Capital Management, LLC | 472.37K | 755.79K | 8.54% |
2023-06-29 | Renaissance Technologies, LLC | 57.32K | 91.72K | 1.04% |
2023-06-29 | Blackrock Inc. | 24.06K | 38.49K | 0.44% |
2023-06-29 | Acadian Asset Management. LLC | 22.54K | 36.06K | 0.41% |
2023-06-29 | Prudential Financial, Inc. | 19.58K | 31.32K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 9.99K | 15.99K | 0.18% |
2023-05-30 | Fidelity Extended Market Index Fund | 8.71K | 14.55K | 0.16% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.59K | 2.66K | 0.03% |
2023-05-30 | Fidelity Total Market Index Fund | 1.59K | 2.65K | 0.03% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 1.27K | 2.15K | 0.02% |
Split | Date |
---|---|
1 : 20 | 2023-01-06 |
1 : 10 | 2020-12-09 |
1 : 20 | 2018-08-13 |
1 : 20 | 2017-08-29 |
1 : 12 | 2016-07-01 |
82 : 1000 | 2015-06-10 |
-
-
$AYTU
Over 9,000,000 shares short with only 11,000,000 shares float
Will take a long time to cover!! -
-
-
-
-
With a combined revenue of $100 million, you have to see the possibility and the growth of this company. Buy and hold and you will be rewarded $ Aytu
-
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022
Aytu adds Neos' established, multi-brand ADHD portfolio, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments
Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu's product portfolio of best-in-class prescription therapeutics and consumer health products
Companies to host joint conference call today at 8:30 am ET -
-
-
$AYTU
Josh now owns 97,500 shares instead of 975,000 so wait for it lol
News is coming quickly -
Aytu BioScience, Inc. (“the Company” or “Aytu”) Board of Directors approved a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 8:00 a.m. Eastern Time on Tuesday, December 8, 2020. The Company's stockholders approved the reverse stock split at an Annual Meeting of Stockholders on April 23, 2020. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing upon market open on December 9, 2020.
-
Aytu BioScience, Inc. (“the Company” or “Aytu”) Board of Directors approved a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 8:00 a.m. Eastern Time on Tuesday, December 8, 2020. The Company's stockholders approved the reverse stock split at an Annual Meeting of Stockholders on April 23, 2020. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing upon market open on December 9, 2020.
-
Josh owns 975,000 shares. How many other stocks ur people have million shares personal?
-
-
-
-
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
accesswire.com • -
Best Penny Stocks? 4 Hot Stocks With News This Week
pennystocks.com • -
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
seekingalpha.com •